Comprehensive Analysis of Genitourinary Collaboration and Licensing Deals (2016-2024) Unveiled
September 25, 2024 09:20 ET
|
Research and Markets
Dublin, Sept. 25, 2024 (GLOBE NEWSWIRE) -- The "Genitourinary Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.The genitourinary therapeutic...
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
September 24, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
American Kidney Fund’s Rare Kidney Disease Advocacy Day on Capitol Hill Seeks to Gather Support for Legislation that will Increase Awareness and Treatment of Rare Kidney Diseases
September 18, 2024 09:59 ET
|
American Kidney Fund
ROCKVILLE, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Members of AKF’s Rare Kidney Disease Action Network (RKDAN) and health care professionals will visit Capitol Hill in Washington, D.C. today to meet...
American Kidney Fund Hosts Annual National Summit on Unknown Causes of Kidney Disease
September 16, 2024 09:49 ET
|
American Kidney Fund
ROCKVILLE, Md., Sept. 16, 2024 (GLOBE NEWSWIRE) -- As part of its ongoing groundbreaking work to advance understanding and patient care of undiagnosed or misdiagnosed causes of kidney disease, the...
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
September 16, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
September 03, 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
Boehringer Ingelheim and Eli Lilly and Company Join American Kidney Fund’s 2024 Corporate Membership Program at ‘Champion’ Level
August 27, 2024 11:01 ET
|
American Kidney Fund
ROCKVILLE, Md., Aug. 27, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announced that Boehringer Ingelheim and Eli Lilly and Company have joined the 2024 class in AKF’s Corporate...
Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
August 14, 2024 07:10 ET
|
Unicycive Therapeutics, Inc.
– On Track to Submit OLC New Drug Application (NDA) by End of August 2024 – LOS ALTOS, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company”...
American Kidney Fund Receives Major Gift from Schattner Foundation to Support Grant Programs and National Virtual Camp
July 22, 2024 09:01 ET
|
American Kidney Fund
ROCKVILLE, Md., July 22, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) has received a $275,000 grant from Rockville-based Schattner Foundation to support AKF’s work on behalf of the 1 in 7...